May 19, 2016 / 12:17 PM / a year ago

BRIEF-Horizon Pharma to buy rights to interferon gamma-1b from Boehringer Ingelheim

May 19 (Reuters) - Horizon Pharma Plc

* Says anticipates a reduction to 2016 adjusted ebitda of approximately $10 million versus prior guidance

* Also licensed u.s., european and canadian intellectual property rights for interferon gamma-1b for treatment of friedreich's ataxia

* Under terms of separate agreement with undisclosed third party, co licensed u.s., european, canadian ip rights for interferon gamma-1b

* Co will immediately begin investing in related manufacturing, supply chain, regulatory,commercial activities for interferon gamma-1b

* To immediately begin investing in related manufacturing, supply chain, regulatory and commercial activities for interferon gamma-1b

* Paid boehringer ingelheim eur5 million upon signing, will pay eur20 million upon closing for rights for interferon gamma-1b in territories outside u.s, canada, japan

* To Acquire Worldwide Rights To Interferon Gamma-1B from boehringer ingelheim international gmbh Source text for Eikon: Further company coverage: (Bengaluru Newsroom: +1-646-223-8780)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below